Anzeige
Mehr »
Samstag, 28.06.2025 - Börsentäglich über 12.000 News
Blockbuster-Bohrergebnisse: Gold-Antimon-Fund in Nevada trifft geopolitischen Nerv
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CWUQ | ISIN: US28658R1068 | Ticker-Symbol:
NASDAQ
27.06.25 | 22:00
1,180 US-Dollar
-5,60 % -0,070
1-Jahres-Chart
CLIMB BIO INC Chart 1 Jahr
5-Tage-Chart
CLIMB BIO INC 5-Tage-Chart

Aktuelle News zur CLIMB BIO Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
18.06.Climb Bio Names Edgar Charles CMO, Cindy Driscoll SVP-Finance-
CLIMB BIO Aktie jetzt für 0€ handeln
18.06.Climb Bio appoints Edgar D. Charles as Chief Medical Officer1
18.06.Climb Bio appoints new chief medical officer and finance executive1
18.06.Climb Bio, Inc. - 8-K, Current Report1
18.06.Climb Bio, Inc.: Climb Bio Appoints Edgar D. Charles, M.D., MSc as Chief Medical Officer178Dr. Charles, Accomplished Immunology-Focused Drug Developer, Brings More Than 20 years of Biopharma Leadership, Clinical Development, and Operations Expertise Company Also Hires Cindy J. Driscoll...
► Artikel lesen
06.06.Oppenheimer initiates coverage on Climb Bio stock with outperform rating1
06.06.Oppenheimer beginnt Berichterstattung über Climb Bio-Aktie mit Outperform-Rating1
05.06.Climb Bio, Inc. - 8-K, Current Report1
04.06.Clym: ARD Money Maker portraitiert Solarpunk-Macher Clym1
22.05.BTIG sets Climb Bio stock Buy rating, $7 target2
19.05.Climb Bio, Inc.: Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)108WELLESLEY HILLS, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases,...
► Artikel lesen
14.05.Climb Bio GAAP EPS of -$0.311
14.05.Climb Bio, Inc. - 10-Q, Quarterly Report-
14.05.Climb Bio, Inc. - 8-K, Current Report1
01.04.Climb Bio, Inc. - S-8, Securities to be offered to employees in employee benefit plans2
25.03.Climb Bio, Inc. - 8-K, Current Report1
25.03.Climb Bio, Inc.: Climb Bio Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Updates569Received Clearance from the U.S. Food and Drug Administration (FDA) for Clinical Trials of Budoprutug in Primary Membranous Nephropathy (pMN), Immune Thrombocytopenia (ITP), and Systemic Lupus Erythematosus...
► Artikel lesen
25.03.Climb Bio, Inc. - 10-K, Annual Report2
24.02.Climb Bio, Inc.: Climb Bio Appoints Perrin Wilson, Ph.D., as Chief Business Officer364WELLESLEY HILLS, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) announced today the appointment of Perrin Wilson, Ph.D. as Chief Business Officer. Dr. Wilson is an accomplished...
► Artikel lesen
10.01.Climb Bio enters licensing deal with Mabworks for CLYM116 development1
Weiter >>
28 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1